Lymphoid neoplasia: Eradication of non-Hodgkin lymphoma through the induction of tumor-specific T-cell immunity by CD20-Flex BiFP

Blood

Volumn 122, Issue 26, 2013, Pages 4230-4236

  Zhao, Lei ^a,b,c   Tong, Qin ^a   Qian, Weizhu ^a,c   Li, Bohua ^a   Zhang, Dapeng ^a,c   Fu, Tuo ^d   Duan, Shuyan ^e   Zhang, Xueguang ^d   Zhao, Jian ^a,b,c   Dai, Jianxin ^a,b,c   Wang, Hao ^a,b,c   Hou, Sheng ^a,b,c   Guo, Yajun ^a,b,c,d,e  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b CHINESE PLA GENERAL HOSPITAL   (China)

^c Shanghai Key Laboratory of Veterinary Science   (China)

^d MEDICAL COLLEGE OF SOOCHOW UNIVERSITY   (China)

^e LIAOCHENG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BISPECIFIC ANTIBODY; CD20 ANTIGEN; CD20 FLEX BISPECIFIC FUSION PROTEIN; HYBRID PROTEIN; RITUXIMAB; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CD135 ANTIGEN; FLT3 PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CANCER RECURRENCE; CELLULAR IMMUNITY; HEMATOPOIESIS; HUMAN; HUMAN CELL; MOUSE; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; TISSUE DISTRIBUTION; ANIMAL; BAGG ALBINO MOUSE; CELL CULTURE; IMMUNOLOGY; LYMPHOMA, B-CELL; LYMPHOMA, NON-HODGKIN; NEOPLASM RECURRENCE, LOCAL; SCID MOUSE; T LYMPHOCYTE; B CELL LYMPHOMA; TUMOR RECURRENCE;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD20; ANTINEOPLASTIC AGENTS; CELLS, CULTURED; FMS-LIKE TYROSINE KINASE 3; HUMANS; LYMPHOMA, B-CELL; LYMPHOMA, NON-HODGKIN; MICE; MICE, INBRED BALB C; MICE, SCID; NEOPLASM RECURRENCE, LOCAL; T-LYMPHOCYTES;

EID: 84894626477     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-04-496554     Document Type: Article

References (44)

1. Shankland KR, Armitage JO, Hancock BW. Non- Hodgkin lymphoma. Lancet. 2012;380(9844): 848-857.
2. Hennessy BT, Hanrahan EO, Daly PA. Non- Hodgkin lymphoma: an update. Lancet Oncol. 2004;5(6):341-353.
3. Calcagno A, Rostagno R, Di Perri G. Anti-CD20 antibody therapy for B-cell lymphomas. N Engl J Med. 2012;367(9):877-878, author reply 878.
4. Boye J, Elter T, Engert A. An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab. Ann Oncol. 2003;14(4): 520-535. (Pubitemid 41295078)
5. Glennie MJ, French RR, Cragg MS, Taylor RP. Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol Immunol. 2007;44(16):3823-3837. (Pubitemid 47332625)
6. Cartron G, Watier H, Golay J, Solal-Celigny P. From the bench to the bedside: ways to improve rituximab efficacy. Blood. 2004;104(9):2635-2642. (Pubitemid 39434941)
7. Davis TA, Grillo-López AJ, White CA, et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol. 2000; 18(17):3135-3143.
8. Hainsworth JD, Litchy S, Burris HA III, et al. Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin's lymphoma. J Clin Oncol. 2002;20(20):4261-4267. (Pubitemid 35191030)
9. Kimby E, Jurlander J, Geisler C, et al; Nordic Lymphoma Group. Long-term molecular remissions in patients with indolent lymphoma treated with rituximab as a single agent or in combination with interferon alpha-2a: a randomized phase II study from the Nordic Lymphoma Group. Leuk Lymphoma. 2008;49(1): 102-112. (Pubitemid 351146889)
10. Cartron G, Zhao-Yang L, Baudard M, et al. Granulocyte-macrophage colony-stimulating factor potentiates rituximab in patients with relapsed follicular lymphoma: results of a phase II study. J Clin Oncol. 2008;26(16):2725-2731.
11. Park S, Jiang Z, Mortenson ED, et al. The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity. Cancer Cell. 2010;18(2):160-170.
12. Uno T, Takeda K, Kojima Y, et al. Eradication of established tumors in mice by a combination antibody-based therapy. Nat Med. 2006;12(6): 693-698. (Pubitemid 43865240)
13. Takeda K, Yamaguchi N, Akiba H, et al. Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy. J Exp Med. 2004;199(4): 437-448. (Pubitemid 38233828)
14. Chao MP, Alizadeh AA, Tang C, et al. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell. 2010;142(5):699-713.
15. Kim PS, Armstrong TD, Song H, et al. Antibody association with HER-2/neu-targeted vaccine enhances CD8 T cell responses in mice through Fc-mediated activation of DCs. J Clin Invest. 2008;118(5):1700-1711. (Pubitemid 351632374)
16. Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer. 2012;12(4): 265-277.
17. Banchereau J, Brière F, Caux C, et al. Immunobiology of dendritic cells. Annu Rev Immunol. 2000;18:767-811. (Pubitemid 30365397)
18. Banchereau J, Palucka AK. Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol. 2005;5(4):296-306. (Pubitemid 40516155)
19. Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature. 2011; 480(7378):480-489.
20. Mocikat R, Braumüller H, Gumy A, et al. Natural killer cells activated by MHC class I(low) targets prime dendritic cells to induce protective CD8 T cell responses. Immunity. 2003;19(4):561-569. (Pubitemid 37311437)
21. Maraskovsky E, Daro E, Roux E, et al. In vivo generation of human dendritic cell subsets by Flt3 ligand. Blood. 2000;96(3):878-884. (Pubitemid 30616851)
22. Maraskovsky E, Brasel K, Teepe M, et al. Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified. J Exp Med. 1996;184(5):1953-1962. (Pubitemid 26404485)
23. Fong L, Hou Y, Rivas A, et al. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc Natl Acad Sci USA. 2001;98(15):8809-8814. (Pubitemid 32678109)
24. Lynch DH, Andreasen A, Maraskovsky E, Whitmore J, Miller RE, Schuh JC. Flt3 ligand induces tumor regression and antitumor immune responses in vivo. Nat Med. 1997;3(6):625-631. (Pubitemid 27264971)
25. Schaefer WW, Regula JTJ, Bähner MM, et al. Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies. Proc Natl Acad Sci USA. 2011; 108(27):11187-11192.
26. Atwell SS, Ridgway JBJ, Wells JAJ, Carter PP. Stable heterodimers from remodeling the domain interface of a homodimer using a phage display library. J Mol Biol. 1997;270(1):26-35.
27. Ridgway JB, Presta LG, Carter P. 'Knobs-intoholes' engineering of antibody CH3 domains for heavy chain heterodimerization. Protein Eng. 1996;9(7):617-621. (Pubitemid 26241639)
28. Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. 1994;83(2): 435-445. (Pubitemid 24030569)
29. Minard-Colin V, Xiu Y, Poe JC, et al. Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage FcgammaRI, FcgammaRIII, and FcgammaRIV. Blood. 2008; 112(4):1205-1213.
30. Olafsen T, Betting D, Kenanova VE, et al. Recombinant anti-CD20 antibody fragments for small-animal PET imaging of B-cell lymphomas. J Nucl Med. 2009;50(9):1500-1508.
31. Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer. 2012;12(4):278-287.
32. Chames P, Baty D. Bispecific antibodies for cancer therapy: the light at the end of the tunnel? MAbs. 2009;1(6):539-547.
33. Beck A, Wurch T, Bailly C, Corvaia N. Strategies and challenges for the next generation of therapeutic antibodies. Nat Rev Immunol. 2010; 10(5):345-352.
34. Abès R, Gélizé E, Fridman WH, Teillaud J-L. Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response. Blood. 2010;116(6):926-934.
35. Beers SA, French RR, Chan HT, et al. Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection. Blood. 2010;115(25):5191-5201.
36. Hiraga J, Tomita A, Sugimoto T, et al. Downregulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance. Blood. 2009;113(20): 4885-4893.
37. Jilani I, O'Brien S, Manshuri T, et al. Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia. Blood. 2003; 102(10):3514-3520. (Pubitemid 37419939)
38. Beum PV, Lindorfer MA, Taylor RP. Within peripheral blood mononuclear cells, antibodydependent cellular cytotoxicity of rituximabopsonized Daudi cells is promoted by NK cells and inhibited by monocytes due to shaving. J Immunol. 2008;181(4):2916-2924.
39. Beum PV, Peek EM, Lindorfer MA, et al. Loss of CD20 and bound CD20 antibody from opsonized B cells occurs more rapidly because of trogocytosis mediated by Fc receptor-expressing effector cells than direct internalization by the B cells. J Immunol. 2011;187(6):3438-3447.
40. Manshouri T, Do K-A, Wang X, et al. Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance. Blood. 2003;101(7):2507-2513. (Pubitemid 36857605)
41. Kennedy AD, Beum PV, Solga MD, et al. Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia. J Immunol. 2004;172(5): 3280-3288. (Pubitemid 38263720)
42. Czuczman MS, Olejniczak S, Gowda A, et al. Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels. Clin Cancer Res. 2008;14(5):1561-1570. (Pubitemid 351413941)
43. Taylor RP, Lindorfer MA. Antigenic modulation and rituximab resistance. Semin Hematol. 2010; 47(2):124-132.
44. Teicher BA. Tumor models for efficacy determination. Mol Cancer Ther. 2006;5(10): 2435-2443. (Pubitemid 44650906)